Biomab injection is used for the treatment of cancer of head and neck and nasophyaryngeal cancer .It is also used to treat Glioma. It is a humanized monoclonal antibody and also a highly selective epidermal growth factor (EGF) receptor antagonist which works to increase angiogenesis, cellular proliferation, apoptosis and cell motility in malignant cells. To buy Biomab or to know its price contact 3S corporation.
Manufacturer : Biocon
Strengths available : 50 mg
Form : Injection
Storage : Store at 2-8 °C
Dosage : Recommended Dose for Head and Neck Cancer: 200 mg once a week for 6 weeks in combination with radiotherapy and/or chemotherapy.
Recommended Dose for Nasopharyngeal Carcinoma: 200 mg once a week for 8 weeks in combinations with radiation. Subsequently, it will be administered a dose of Biomab EGFR 200 mg every 15 days (maintenance dose) until the patient’s general condition permits.
Glioma: Adults: Recommended Dose: 200 mg weekly in combination with conventional radiation treatment. Subsequently, it will be administered a dose of Biomab EGFR 200 mg every 15 days (maintenance dose) until the patient’s general condition permits.
Children and Adolescents: Recommended Dose: Monotherapy in 2 consecutive phases, induction phase and consolidation phase. During induction phase, Biomab EGFR is given at 150 mg/m2 body surface area (BSA) weekly for 6 weeks.
Common side effects are fever, chills, nausea, vomiting, asthenia, hypotension or herpertension, flushing, dryness of mouth, rash, headache, fluctuation in blood pressure, dizziness and light headedness.
Pack of 4×10 ml
3S Corporation is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of Biomab Nimotuzumab 50 mg based in India - To buy Biomab Nimotuzumab 50 mg or know its cost price contact us here.
We supply & sell Biomab Nimotuzumab 50 mg for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.